AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
1-Year Est. Return
18.84%
1 Year Est. Return
+18.84%
AUM
$135M
AUM Growth
-$1.28M
(-0.95%)
Holding
245
Top Buys
| 1 | +$2.73M | |
| 2 | +$2.36M | |
| 3 | +$2.06M | |
| 4 |
Neurocrine Biosciences
NBIX
|
+$1.79M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$1.37M |
Top Sells
| 1 | +$4.17M | |
| 2 | +$3.36M | |
| 3 | +$3.04M | |
| 4 |
United Therapeutics
UTHR
|
+$2.96M |
| 5 |
ONC
BeOne Medicines Ltd
ONC
|
+$2.13M |
Sector Composition
| 1 | Healthcare | 57.92% |
| 2 | Real Estate | 14.45% |
| 3 | Financials | 7.05% |
| 4 | Industrials | 3.2% |
| 5 | Technology | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Zscaler
ZS
$47.5B
| $25.3K | 0.02% |
148
-4
|
|
||
227
Super Micro Computer
SMCI
$31B
| $20.4K | 0.02% |
490
-20
|
|
||
228
Snowflake
SNOW
$81.6B
| $18.8K | 0.01% |
164
-5
|
|
||
229
Cabaletta Bio
CABA
$261M
| – | – |
-70,000
|
|
||
230
DocGo
DCGO
$113M
| – | – |
-650,000
|
|
||
231
iShares Russell 1000 Value ETF
IWD
$64.4B
| – | – |
-2,762
|
|
||
232
KalVista Pharmaceuticals
KALV
$561M
| – | – |
-2,500
|
|
||
233
Pacira BioSciences
PCRX
$1.03B
| – | – |
-117,500
|
|
||
234
uniQure
QURE
$3.57B
| – | – |
-460,000
|
|
||
235
Aurinia Pharmaceuticals
AUPH
$1.52B
| – | – |
-80,000
|
|
||
236
BioCryst Pharmaceuticals
BCRX
$1.4B
| – | – |
-675,000
|
|
||
237
Invesco S&P 500 Pure Value ETF
RPV
$1.35B
| – | – |
-5,715
|
|
||
238
iShares MSCI Turkey ETF
TUR
$158M
| – | – |
-2,894
|
|
||
239
Ventyx Biosciences
VTYX
$280M
| – | – |
-10,000
|
|
||
|
NARI
240
DELISTED
Inari Medical, Inc. Common Stock
NARI
| – | – |
-15,000
|
|
||
|
CERE
241
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-42,500
|
|